Novo Nordisk A/S is likely to contribute about half of Denmark’s economic expansion this year, helping the nation to ...
Denmark: The nation’s flourishing drugmaking industry, mostly known for Novo’s obesity drugs, has been responsible for much ...
The UAE has partnered with Novo Nordisk Pharma Gulf to develop a national scientific guide for obesity management and weight ...
Novo Nordisk’s Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a ...
Siding With Novo and Lilly, Court Agrees to First Tackle ‘Cross Cutting Issues” in GLP-1 Litigations
In agreeing with Novo Nordisk and Eli Lilly, Pennsylvania judge Karen Spencer Marston said the court should first settle ...
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy ...
Novo Nordisk (NVO) posts new data to show the potential of its weight loss therapy semaglutide in reducing heart failure risk ...
In a report released on August 28, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK1,100.00. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results